Literature DB >> 10991875

Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

W R Kirkpatrick1, R K McAtee, A W Fothergill, M G Rinaldi, T F Patterson.   

Abstract

Voriconazole (VRC) was evaluated in an immunosuppressed-guinea pig model of invasive aspergillosis. VRC was more effective than amphotericin B or similar doses of itraconazole in the clearance of Aspergillus from tissues. VRC treatment regimens improved survival and significantly reduced tissue colony counts compared with those of controls.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10991875      PMCID： PMC90166          DOI： 10.1128/AAC.44.10.2865-2868.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model.

Authors:  T F Patterson; P Miniter; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

2.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors:  K L Oakley; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.

Authors:  M Lozano-Chiu; S Arikan; V L Paetznick; E J Anaissie; J H Rex
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

4.  Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs.

Authors:  M V Martin; J Yates; C A Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 5.  New antifungal agents.

Authors:  J R Graybill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

6.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

Authors:  A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.

Authors:  T F Patterson; D George; R Ingersoll; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

8.  Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.

Authors:  J R Graybill; S R Kaster
Journal:  Am Rev Respir Dis       Date:  1984-02

9.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

10.  Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.

Authors:  T F Patterson; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191
View more
  26 in total

Review 1.  Voriconazole: in the treatment of invasive aspergillosis.

Authors:  Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 5.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

7.  Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.

Authors:  Emily E Rosowski; Jiaye He; Jan Huisken; Nancy P Keller; Anna Huttenlocher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

8.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.